Table 3.

Reported Adverse Effects, Categorized and Graded According to CTCAE v3.0

Adverse Effect	Grade						Total	Percentage of Grade 3-5 Adverse Effects
	0	1	2	3	4	5
Leukopenia	2	4	20	19	1	0	46	43.4
Neutropenia	1	3	3	19	20	0	46	84.7
Thrombocytopenia	17	19	5	3	2	0	46	10.8
Anemia	4	10	27	3	2	0	46	10.8
Hemolysis	46	0	0	0	0	0	46	0
Other hematologic	43	0	1	2	0	0	46	4.3
Allergy	40	3	0	3	0	0	46	6.5
Auditory	43	0	2	1	0	0	46	2.1
Cardiovascular	39	3	2	1	1	0	46	4.3
Coagulation	45	0	1	0	0	0	46	0
Constitutional	33	8	4	1	0	0	46	2.1
Fatigue	9	14	19	4	0	0	46	8.7
Alopecia	8	7	31	0	0	0	46	0
Dermatologic	36	8	2	0	0	0	46	0
Endocrine	44	2	0	0	0	0	46	0
GI	18	12	14	2	0	0	46	4.3
Nausea	17	20	8	1	0	0	46	2.1
Vomiting	35	7	3	1	0	0	46	2.1
Diarrhea	35	8	2	1	0	0	46	2.1
Stomatitis	45	1	0	0	0	0	46	0
Genitourinary/renal	45	1	0	0	0	0	46	0
Hemorrhage	43	1	2	0	0	0	46	0
Hepatic	45	0	0	1	0	0	46	2.1
Infection/fever	46	0	0	0	0	0	46	0
Febrile neutropenia	45	0	0	1	0	0	46	2.1
Metabolic	23	18	4	1	0	0	46	2.1
Creatinine	44	2	0	0	0	0	46	0
Musculoskeletal	41	2	2	1	0	0	46	2.1
Neurologic	40	0	4	2	0	0	46	4.3
Neuromotor	44	0	2	0	0	0	46	0
Sensory neuropathy	14	15	12	5	0	0	46	10.8
Ocular/visual	43	2	1	0	0	0	46	0
Pain	35	3	6	0	2	0	46	4.3
Myalgia	35	3	7	1	0	0	46	2.1
Arthralgia	36	4	6	0	0	0	46	0
Pulmonary	37	5	2	2	0	0	46	4.3

Abbreviation: CTCAE, Common Terminology Criteria for Adverse Events.